They will also likely ask about any new symptoms or treatment side effects. The five-year survival rate for HR+/HER2- breast cancer is 100% for cancer that doesn't spread, 90.5% if the cancer spreads ...

ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

The US company also sells a small-molecule HER2 inhibitor – Tukysa (tucatinib ... While the licensing deal with Seagen tops up its finances, the scale well below the $6.9 billion bundle ...

Neoadjuvant disitamab vedotin plus perioperative toripalimab showed promising efficacy and acceptable safety in patients with HER2-expressing MIBC, according to Xinan Sheng, MD.

Enhertu improved overall survival versus chemotherapy in HER2-positive metastatic gastric cancer, prompting an interim ...

HER2 (also known as ERBB2) is a key oncogene in breast cancer and is found in 2–4% of patients with non-small-cell lung cancer (NSCLC), typically in female individuals, who are non-smokers, and have ...

The FDA has granted priority review to the new drug application for zongertinib to treat adults with unresectable or metastatic, HER2-mutant NSCLC who have received prior systemic therapy.